NanoLogix, Inc. (NNLX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNanoLogix, Inc. (NNLX) trades at $0.00008. NanoLogix, Inc. is a biotechnology company specializing in rapid diagnostics test kits for detecting viable bacteria and microorganisms. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for NNLX: NNLX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
NanoLogix, Inc. (NNLX) Healthcare & Pipeline Overview
NanoLogix, Inc. is a biotechnology company focused on live cell and rapid diagnostics, providing solutions for detecting viable bacteria and microorganisms across medical, defense, and industrial sectors. Their BioNanoPore kit and FlatPack Petri Plates cater to a diverse range of testing applications, positioning them within the broader biotechnology landscape.
What Is the Investment Thesis for NNLX?
NanoLogix operates in the biotechnology sector, specifically focusing on rapid diagnostics. The company's negative profit margin of -3631.2% and gross margin of -1994.6% indicate significant challenges in achieving profitability. While the company's products, such as the BioNanoPore kit and FlatPack Petri Plates, cater to a diverse range of sectors, including medical and defense, the lack of dividend yield suggests that investors are not currently receiving direct returns. Key value drivers would include successful commercialization of their diagnostic kits and expansion into new markets. Upcoming catalysts could include positive results from ongoing research and development efforts, or strategic partnerships that enhance market reach. However, the high beta of -34.75 indicates extreme volatility, and the company's financial performance needs to improve significantly to justify investment.
Based on FMP financials and quantitative analysis
NNLX Key Highlights
Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity and higher risk.
- P/E Ratio of -0.01 reflects the company's lack of profitability, as earnings are negative.
- Profit Margin of -3631.2% demonstrates significant operational inefficiencies and high costs relative to revenue.
- Gross Margin of -1994.6% suggests that the company is selling its products at a loss, indicating unsustainable pricing or high production costs.
- Beta of -34.75 indicates an inverse correlation with the market, but the magnitude suggests data anomalies or inaccuracies.
Who Are NNLX's Competitors?
NNLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.65 | +0.06% | $88.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $10.24 | -0.10% | $93.6M | 78 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $170M | 75 5-pillar |
| NAGE Niagen Bioscience Inc | $2.44 | +0.41% | $190M | 70 5-pillar |
| QTTB Q32 Bio Inc. | $8.45 | -2.31% | $252M | 67 5-pillar |
| CLYM Climb Bio, Inc. | $8.81 | -13.54% | $506M | 67 5-pillar |
| ZVRA Zevra Therapeutics, Inc. | $9.53 | -2.85% | $566M | 91 5-pillar |
| MDXG MiMedx Group, Inc. | $3.85 | -1.53% | $570M | 88 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NNLX's Key Strengths?
Proprietary BioNanoPore technology.
- Rapid diagnostics capabilities.
- Diverse application across multiple sectors.
- Established customer base in medical and scientific entities.
What Are NNLX's Weaknesses?
Negative profit and gross margins.
- Limited market capitalization.
- High beta indicating extreme volatility.
- Dependence on a limited number of products.
What Are the Key Risks for NNLX?
Intense competition from larger and more established biotechnology companies.
- Regulatory hurdles and delays in obtaining approvals for new products.
- Negative profit and gross margins indicating financial instability.
- Technological obsolescence and the emergence of competing technologies.
- Limited market capitalization and liquidity on the OTC market.
What Threats Does NNLX Face?
- Intense competition in the biotechnology industry.
- Regulatory hurdles and approval processes.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
What Are NNLX's Competitive Advantages?
- Proprietary BioNanoPore technology offers a unique approach to diagnostics.
- Specialized FlatPack Petri Plates cater to specific microorganism cultivation needs.
- Focus on rapid diagnostics provides a competitive edge in time-sensitive applications.
What Does NNLX Do?
NanoLogix, Inc., based in Hubbard, Ohio, is a biotechnology company dedicated to developing and commercializing rapid diagnostics test kits. Founded with the goal of providing faster and more accurate detection of viable bacteria and other microorganisms, the company has focused on creating innovative solutions for various sectors, including medical, national defense, homeland security, pharmaceutical, industrial, veterinary, and environmental testing. NanoLogix's core product offerings include the BioNanoPore kit, which utilizes a water-permeable membrane to interact with organic and inorganic molecules, as well as proteins, and FlatPack Petri Plates, designed for the isolation and cultivation of diverse microorganisms under both aerobic and anaerobic conditions. These products are sold to established medical and scientific entities, such as laboratories, medical institutions, universities, businesses, and research establishments. The company's focus on rapid diagnostics addresses a critical need for timely and accurate detection in various applications, contributing to improved outcomes in healthcare, safety, and environmental monitoring. NanoLogix continues to refine its technologies and expand its product offerings to meet the evolving needs of its diverse customer base.
What Products and Services Does NNLX Offer?
- Develops live cell and rapid diagnostics test kits.
- Creates products that detect viable bacteria and other microorganisms.
- Offers the BioNanoPore kit, which uses a water-permeable membrane.
- Provides FlatPack Petri Plates for microorganism isolation and cultivation.
- Serves medical, national defense, and industrial sectors.
- Offers solutions for pharmaceutical, veterinary, and environmental testing.
How Does NNLX Make Money?
- Sells diagnostic test kits to laboratories and medical institutions.
- Generates revenue through direct sales to universities and research establishments.
- Focuses on providing rapid and accurate detection solutions.
What Industry Does NNLX Operate In?
NanoLogix operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory hurdles. The market for rapid diagnostics is growing, driven by the need for faster and more accurate detection of diseases and pathogens. Key trends include the development of point-of-care diagnostics and the increasing use of molecular diagnostics. NanoLogix competes with other biotechnology companies that offer similar diagnostic solutions. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong partnerships with key customers.
Who Are NNLX's Key Customers?
- Laboratories
- Medical Institutions
- Universities
- Research Establishments
- Businesses in various sectors
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
NanoLogix, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hubbard, US. The company is led by CEO Bret T. Barnhizer. NNLX has traded publicly since 2009.
NNLX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
NNLX Latest News
No recent news available for NNLX.
NNLX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NNLX.
Price Targets
Wall Street price target analysis for NNLX.
NNLX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NNLX; grades run from A+ (80-100) to F (below 30).
Leadership: Bret T. Barnhizer
CEO
Bret T. Barnhizer serves as the CEO of NanoLogix, Inc. His background includes experience in business development, strategic planning, and financial management within the biotechnology and healthcare sectors. He has a proven track record of leading companies through periods of growth and innovation. Barnhizer's expertise lies in identifying market opportunities, building strong teams, and securing funding for research and development initiatives. He also possesses strong leadership skills and a commitment to driving shareholder value.
Track Record: Under Bret T. Barnhizer's leadership, NanoLogix has focused on refining its core technologies and expanding its product offerings. Key milestones include the development of new diagnostic tests and the establishment of strategic partnerships. Barnhizer has also overseen efforts to improve the company's financial performance and secure additional funding. His strategic decisions have been instrumental in positioning NanoLogix for future growth.
NNLX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NanoLogix may not meet the minimum financial standards or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to adhere to the same listing standards as those on major exchanges like NYSE or NASDAQ, resulting in less transparency for investors.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in NNLX.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- Uncertainty regarding the company's long-term viability.
- Risk of delisting or suspension from the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's competitive position and market opportunities.
- Evaluate the company's intellectual property and technology.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation for several years.
- Products are used in medical and scientific applications.
- Company has established relationships with customers in various sectors.
- CEO has relevant experience in the biotechnology industry.
- Company maintains a website and provides contact information.
Common Questions About NNLX (Healthcare)
What do analysts say about NNLX stock?
There is currently no available analyst coverage or consensus regarding NanoLogix (NNLX) stock, likely due to its micro-cap status and trading on the OTC market. Key valuation metrics such as price targets and ratings are not available.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or unreliable.